表纸
市场调查报告书
商品编码
245971

再生不良性贫血:开发中产品分析

Aplastic Anemia (Hematology) - Drugs in Development, 2021

出版日期: | 出版商: Global Markets Direct | 英文 138 Pages | 订单完成后即时交付

价格

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

  • 全貌
  • 简介
  • 目录
简介

再生不良性贫血是具有末梢性全血球减少症及骨髓形成不全等特征的骨髓损伤症。症状有疲劳,肤色青白,心律急速或不规则,运动性喘不过气,鼻血,齿龈出血,长刀伤造成的出血,皮疹,晕眩,头痛等。危险因素有暴露在有毒的化学物质,癌症的高辐射剂量放射治疗或化疗,特定的血液疾病,自体免疫不全,严重的感染疾病等。治疗有使用免疫抑制药与干细胞移植等。

本报告提供全球各国治疗再生不良性贫血所用的开发中产品开发情形相关分析,提供开发中产品的最新趋势,及临床实验的各阶段产品一览,主要企业简介,主要药物概要(产品概要,功能机制,研究开发(R&D)的发展情形),最新的产业趋势等调查结果。

简介

  • 分析范围

再生不良性贫血概要

治疗药的开发

  • 再生不良性贫血开发中产品:概要
  • 各企业的开发平台
  • 企业开发中的产品

治疗药的评估

  • 标的别
  • 各作用机制
  • 各给药途径
  • 各分子类型

再生不良性贫血开发治疗药的企业

  • 3SBio Inc
  • Acceleron Pharma Inc
  • Amgen Inc
  • BioLineRx Ltd
  • F. Hoffmann-La Roche Ltd
  • Gamida Cell Ltd
  • Novartis AG
  • Pluristem Therapeutics Inc
  • Regen BioPharma Inc

药物简介

暂停的计划

开发中止的产品

再生不良性贫血相关产品的开发的里程碑

  • 值得注意的最新趋势·新闻稿

附录

图表一览

目录
Product Code: GMDHC13083IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Aplastic Anemia - Drugs In Development, 2021, provides an overview of the Aplastic Anemia (Hematological Disorders) pipeline landscape.Aplastic anemia is a syndrome of bone marrow failure characterized by peripheral pancytopenia and marrow hypoplasia. Symptoms include fatigue, pale skin, rapid or irregular heart rate, shortness of breath with exertion, nosebleeds and bleeding gums, prolonged bleeding from cuts, skin rash, dizziness and headache. Risk factors include exposure to toxic chemicals, treatment with high-dose radiation or chemotherapy for cancer, certain blood diseases, autoimmune disorders and serious infections. Treatment includes immunosuppressants and stem cell transplant.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Aplastic Anemia - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Aplastic Anemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Aplastic Anemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Aplastic Anemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 6, 2, 5 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Aplastic Anemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Aplastic Anemia (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Aplastic Anemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Aplastic Anemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Aplastic Anemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Aplastic Anemia (Hematological Disorders)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Aplastic Anemia (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Aplastic Anemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Aplastic Anemia - Overview
  • Aplastic Anemia - Therapeutics Development
  • Aplastic Anemia - Therapeutics Assessment
  • Aplastic Anemia - Companies Involved in Therapeutics Development
  • Aplastic Anemia - Drug Profiles
  • Aplastic Anemia - Dormant Projects
  • Aplastic Anemia - Discontinued Products
  • Aplastic Anemia - Product Development Milestones
  • Appendix

List of Tables

List of Tables

  • Number of Products under Development for Aplastic Anemia, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Aplastic Anemia - Pipeline by Acceleron Pharma Inc, 2021
  • Aplastic Anemia - Pipeline by Amgen Inc, 2021
  • Aplastic Anemia - Pipeline by ASC Therapeutics Inc, 2021
  • Aplastic Anemia - Pipeline by Bellicum Pharmaceuticals Inc, 2021
  • Aplastic Anemia - Pipeline by BioLineRx Ltd, 2021
  • Aplastic Anemia - Pipeline by Cell Source Inc, 2021
  • Aplastic Anemia - Pipeline by Cellenkos Inc, 2021
  • Aplastic Anemia - Pipeline by Elixirgen Therapeutics Inc, 2021
  • Aplastic Anemia - Pipeline by F. Hoffmann-La Roche Ltd, 2021
  • Aplastic Anemia - Pipeline by Gamida Cell Ltd, 2021
  • Aplastic Anemia - Pipeline by Hangzhou Zede Pharmaceutical Technology Co Ltd, 2021
  • Aplastic Anemia - Pipeline by HemoGenyx Pharmaceuticals Plc, 2021
  • Aplastic Anemia - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2021
  • Aplastic Anemia - Pipeline by Novartis AG, 2021
  • Aplastic Anemia - Pipeline by Ono Pharmaceutical Co Ltd, 2021
  • Aplastic Anemia - Pipeline by Pfizer Inc, 2021
  • Aplastic Anemia - Pipeline by Regen BioPharma Inc, 2021
  • Aplastic Anemia - Pipeline by Regeneron Pharmaceuticals Inc, 2021
  • Aplastic Anemia - Dormant Projects, 2021
  • Aplastic Anemia - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Aplastic Anemia, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021